MX2019001672A - Composiciones de poxvirus quiméricos y usos de las mismas. - Google Patents
Composiciones de poxvirus quiméricos y usos de las mismas.Info
- Publication number
- MX2019001672A MX2019001672A MX2019001672A MX2019001672A MX2019001672A MX 2019001672 A MX2019001672 A MX 2019001672A MX 2019001672 A MX2019001672 A MX 2019001672A MX 2019001672 A MX2019001672 A MX 2019001672A MX 2019001672 A MX2019001672 A MX 2019001672A
- Authority
- MX
- Mexico
- Prior art keywords
- chemeric
- poxvirus
- things
- compositions
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24151—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662372408P | 2016-08-09 | 2016-08-09 | |
| US201762519010P | 2017-06-13 | 2017-06-13 | |
| PCT/US2017/046163 WO2018031694A1 (en) | 2016-08-09 | 2017-08-09 | Chimeric poxvirus compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019001672A true MX2019001672A (es) | 2019-06-06 |
Family
ID=61163330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019001672A MX2019001672A (es) | 2016-08-09 | 2017-08-09 | Composiciones de poxvirus quiméricos y usos de las mismas. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12084687B2 (https=) |
| EP (1) | EP3497209A4 (https=) |
| JP (4) | JP7023929B2 (https=) |
| KR (3) | KR20230113832A (https=) |
| CN (3) | CN118853594A (https=) |
| AU (2) | AU2017311380A1 (https=) |
| CA (1) | CA3033512A1 (https=) |
| MX (1) | MX2019001672A (https=) |
| RU (2) | RU2021128158A (https=) |
| WO (1) | WO2018031694A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| EP4122492A1 (en) | 2015-02-25 | 2023-01-25 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| KR20180006916A (ko) | 2015-04-17 | 2018-01-19 | 메모리얼 슬로안-케터링 캔서 센터 | 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도 |
| CN109152827B (zh) | 2016-02-25 | 2023-07-21 | 纪念斯隆凯特琳癌症中心 | 重组mva或表达人flt3l的mvaδe3l及其作为抗固体肿瘤的免疫治疗剂的用途 |
| JP7025339B2 (ja) | 2016-02-25 | 2022-02-24 | メモリアル スローン ケタリング キャンサー センター | 癌免疫療法のための、チミジンキナーゼの欠失を伴い、ヒトｆｌｔ３ｌまたはｇｍ－ｃｓｆの発現を伴うかまたは伴わない、複製可能な弱毒化ワクシニアウイルス |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| WO2018031694A1 (en) * | 2016-08-09 | 2018-02-15 | City Of Hope | Chimeric poxvirus compositions and uses thereof |
| JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための組成物および方法 |
| EP3621646A4 (en) | 2017-05-12 | 2021-06-02 | Memorial Sloan Kettering Cancer Center | VACCINIA VIRUS MUTANTS FOR CANCER IMMUNOTHERAPY |
| CN111163803B (zh) * | 2017-08-11 | 2025-05-09 | 希望之城公司 | 表达car t细胞靶物的溶瘤病毒及其用途 |
| JP7549303B2 (ja) | 2018-01-22 | 2024-09-11 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞の使用方法 |
| CN112105382A (zh) | 2018-02-23 | 2020-12-18 | 恩多塞特公司 | 用于car t细胞疗法的顺序方法 |
| JP2021516957A (ja) * | 2018-03-07 | 2021-07-15 | トランジェーヌＴｒａｎｓｇｅｎｅ | パラポックスウイルスベクター |
| US20210052660A1 (en) * | 2018-04-30 | 2021-02-25 | City Of Hope | Neural stem cell compositions including chimeric poxviruses for cancer treatment |
| BR112021004692A2 (pt) | 2018-09-15 | 2021-06-08 | Memorial Sloan Kettering Cancer Center | poxvírus recombinantes para imunoterapia de câncer |
| CN113583977B (zh) * | 2020-04-30 | 2025-06-06 | 杭州康万达医药科技有限公司 | 可受微小rna调控的分离的重组溶瘤痘病毒及其应用 |
| GB2614309A (en) | 2021-12-24 | 2023-07-05 | Stratosvir Ltd | Improved vaccinia virus vectors |
| WO2023213763A1 (en) * | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| CA3261778A1 (en) | 2022-08-18 | 2024-02-22 | Transgene | CHIMERIC POXVIRUSES |
| WO2024245722A2 (en) * | 2023-05-26 | 2024-12-05 | Probiogen Ag | Rapid selection system for the generation of recombinant enveloped viruses |
| WO2025184411A1 (en) | 2024-02-27 | 2025-09-04 | Calidi Biotherapeutics (Nevada), Inc. | Serum-resistant eev viruses and uses thereof |
| CN120718864B (zh) * | 2025-08-28 | 2025-11-28 | 山东农业大学 | 一种高度不成熟鸭坦布苏病毒及其培养方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT406376B (de) | 1998-01-16 | 2000-04-25 | Immuno Ag | Chimäres poxvirus enthaltend eine retrovirale vektorkomponente |
| AU2001252998A1 (en) | 2000-03-28 | 2001-10-08 | University Of Rochester | Methods of producing a library and methods of selecting polynucletides |
| WO2004048582A2 (en) * | 2002-11-25 | 2004-06-10 | Bavarian Nordic A/S | Recombinant poxvirus comprising at least two cowpox ati promoters |
| EP1644492B1 (en) * | 2003-06-18 | 2009-01-07 | Genelux Corporation | Modified recombinant vaccinia viruses, uses thereof |
| EP2426142A3 (en) | 2006-10-16 | 2012-06-13 | Genelux Corporation | Modified vaccinia virus strains for use in a diagnostic and therapeutic method |
| KR101542275B1 (ko) * | 2007-11-19 | 2015-08-06 | 트랜스진 에스.에이. | 폭스바이러스성 온콜리틱 벡터 |
| WO2011125469A1 (ja) * | 2010-04-09 | 2011-10-13 | 国立大学法人東京大学 | マイクロrna制御組換えワクシニアウイルス及びその使用 |
| CN114262690A (zh) | 2011-04-15 | 2022-04-01 | 吉恩勒克斯公司 | 减毒的痘苗病毒的克隆毒株及其使用方法 |
| CN104768567B (zh) | 2012-05-18 | 2017-07-11 | 奥塔哥创业有限公司 | 用于伤口愈合的联合治疗和组合物 |
| WO2015103438A2 (en) | 2014-01-02 | 2015-07-09 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| WO2018031694A1 (en) * | 2016-08-09 | 2018-02-15 | City Of Hope | Chimeric poxvirus compositions and uses thereof |
-
2017
- 2017-08-09 WO PCT/US2017/046163 patent/WO2018031694A1/en not_active Ceased
- 2017-08-09 RU RU2021128158A patent/RU2021128158A/ru unknown
- 2017-08-09 AU AU2017311380A patent/AU2017311380A1/en not_active Abandoned
- 2017-08-09 KR KR1020237024342A patent/KR20230113832A/ko not_active Ceased
- 2017-08-09 EP EP17840232.7A patent/EP3497209A4/en active Pending
- 2017-08-09 KR KR1020257014373A patent/KR20250067190A/ko active Pending
- 2017-08-09 CA CA3033512A patent/CA3033512A1/en active Pending
- 2017-08-09 MX MX2019001672A patent/MX2019001672A/es unknown
- 2017-08-09 JP JP2019507161A patent/JP7023929B2/ja active Active
- 2017-08-09 CN CN202410528631.4A patent/CN118853594A/zh active Pending
- 2017-08-09 CN CN201780062335.8A patent/CN110199018B/zh active Active
- 2017-08-09 RU RU2019106319A patent/RU2757002C2/ru active
- 2017-08-09 US US16/324,541 patent/US12084687B2/en active Active
- 2017-08-09 CN CN202410528486.XA patent/CN118834840A/zh active Pending
- 2017-08-09 KR KR1020197006987A patent/KR102557818B1/ko active Active
-
2022
- 2022-02-08 JP JP2022017693A patent/JP7395628B2/ja active Active
-
2023
- 2023-11-20 AU AU2023270200A patent/AU2023270200B2/en active Active
- 2023-11-28 JP JP2023200433A patent/JP7631485B2/ja active Active
-
2024
- 2024-07-17 US US18/776,109 patent/US20250084384A1/en active Pending
-
2025
- 2025-02-04 JP JP2025016649A patent/JP2025072482A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR102557818B1 (ko) | 2023-07-20 |
| CN118853594A (zh) | 2024-10-29 |
| JP7023929B2 (ja) | 2022-02-22 |
| US20190218522A1 (en) | 2019-07-18 |
| RU2757002C2 (ru) | 2021-10-08 |
| JP2019524131A (ja) | 2019-09-05 |
| EP3497209A4 (en) | 2020-07-29 |
| KR20250067190A (ko) | 2025-05-14 |
| CN110199018B (zh) | 2024-06-07 |
| RU2019106319A3 (https=) | 2021-03-17 |
| JP7631485B2 (ja) | 2025-02-18 |
| WO2018031694A1 (en) | 2018-02-15 |
| RU2019106319A (ru) | 2020-09-17 |
| BR112019002646A2 (pt) | 2019-10-08 |
| KR20190038626A (ko) | 2019-04-08 |
| KR20230113832A (ko) | 2023-08-01 |
| CA3033512A1 (en) | 2018-02-15 |
| JP2022065034A (ja) | 2022-04-26 |
| US20250084384A1 (en) | 2025-03-13 |
| AU2023270200B2 (en) | 2026-02-05 |
| AU2017311380A1 (en) | 2019-03-28 |
| AU2023270200A1 (en) | 2024-01-25 |
| US12084687B2 (en) | 2024-09-10 |
| CN110199018A (zh) | 2019-09-03 |
| RU2021128158A (ru) | 2022-04-07 |
| JP2025072482A (ja) | 2025-05-09 |
| JP7395628B2 (ja) | 2023-12-11 |
| EP3497209A1 (en) | 2019-06-19 |
| CN118834840A (zh) | 2024-10-25 |
| JP2024026191A (ja) | 2024-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019001672A (es) | Composiciones de poxvirus quiméricos y usos de las mismas. | |
| CO2020016619A2 (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso | |
| CO2018008761A2 (es) | Derivados de maitansinoide, conjugados de los mismos métodos de uso | |
| MX2018016273A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| CO2017010890A2 (es) | Derivados de maitansinoide, conjugados del mismo, y metodos de uso | |
| CY1122227T1 (el) | Ρυθμιση δραστικοτητας συμπληρωματος | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| ECSP17073743A (es) | Moduladores de k-ras | |
| MX394380B (es) | Compuestos dinucleótidos cíclicos para eltratamiento de cáncer | |
| UY37564A (es) | Aislados de lysinibacillus y usos de los mismos | |
| MX2018003491A (es) | Represores de htt y usos de estos. | |
| MX387596B (es) | Degradadores selectivos del receptor de estrógeno y sus usos. | |
| CR20160241A (es) | Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infección por virus de la hepatitis b | |
| CO2017004736A2 (es) | Péptidos macrociclicos útiles como inmunomoduladores | |
| MX2018007288A (es) | Anticuerpos neutralizantes para el virus de inmunodeficiencia humana. | |
| CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| MX2016016301A (es) | Procesos de siembra en serie y usos de los mismos. | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
| MX2018001755A (es) | Vacuna contra viruela para tratamiento del cancer. | |
| PE20170088A1 (es) | Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos | |
| CL2016002245A1 (es) | Anticuerpos específicos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos. | |
| MX2020002251A (es) | Compuestos espirociclicos y sus metodos de preparacion y uso. | |
| BR112016017112A2 (pt) | Composições de apilimod e métodos de uso das mesmas |